Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects

• Published in: Antimicrobial agents and chemotherapy Vol. 62; no. 3
• Main Authors: Kosloski, Matthew P., Zhao, Weihan, Marbury, Thomas C., Preston, Richard A., Collins, Michael G., Pugatch, David, Mensa, Federico, Kort, Jens, Liu, Wei
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.03.2018
• Subjects: Adult; Aged; Antiviral Agents; Antiviral Agents - blood; Antiviral Agents - pharmacokinetics; Area Under Curve; Benzimidazoles; Benzimidazoles - blood; Benzimidazoles - pharmacokinetics; Drug Administration Schedule; Drug Therapy, Combination - methods; Female; Glomerular Filtration Rate - physiology; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Kidney Failure, Chronic - blood; Kidney Failure, Chronic - physiopathology; Male; Middle Aged; Quinoxalines; Quinoxalines - blood; Quinoxalines - pharmacokinetics; Renal Dialysis; Renal Insufficiency, Chronic; Renal Insufficiency, Chronic - blood; Renal Insufficiency, Chronic - physiopathology; Sulfonamides; Sulfonamides - blood; Sulfonamides - pharmacokinetics; chronic kidney disease; pibrentasvir; hemodialysis; hepatitis C virus; pharmacokinetics; glecaprevir; renal impairment

Hepatitis C virus (HCV) infection is an independent risk factor for developing chronic renal impairment and end-stage renal disease. Limited treatment options are available for HCV genotype 2, 3, 5, and 6 infections in patients with an estimated glomerular filtration rate (eGFR) of <30 ml/min. Gl...